In STEMI, C-reactive protein at presentation predicts MI, death

In STEMI, C-reactive protein at presentation predicts MI, death
For patients with ST-segment elevation myocardial infarction, high-sensitivity C-reactive protein measurements at presentation predict subsequent nonfatal myocardial infarction and cardiac death; and for patients with acute coronary syndromes, fetuin-A and C-reactive protein have prognostic value, according to two studies published in the Jan. 1 issue of The American Journal of Cardiology.

(HealthDay)—For patients with ST-segment elevation myocardial infarction (STEMI), high-sensitivity C-reactive protein (hsCRP) measurements at presentation predict subsequent nonfatal MI and cardiac death; and for patients with acute coronary syndromes (ACS), fetuin-A and CRP have prognostic value, according to two studies published in the Jan. 1 issue of The American Journal of Cardiology.

Stamatis S. Makrygiannis, M.D., from the "Tzanio" Hospital of Piraeus in Greece, and colleagues determined hsCRP measurements at presentation and at 24, 48, and 72 hours in 861 patients admitted for STEMI who received intravenous thrombolytic therapy within the first six hours of the index pain. Over a median follow-up of 3.5 years, the researchers found that hsCRP levels at presentation independently predicted nonfatal MI and cardiac death (relative risk, 2.8 and 2.1, respectively), while levels at 24 hours predicted neither. Levels of hsCRP at 48 and 72 hours significantly predicted cardiac death (relative risk, 3.2 and 3.9, respectively) but not MI.

Pascal Lim, M.D., Ph.D., from the AP-HP-University Hospital Henri Mondor in Creteil, France, and colleagues examined the prognostic value of fetuin-A adjusted for CRP value and Global Registry of Acute Coronary Events in 754 patients with ACS. The researchers found that the one-year was 10 percent overall, 17 percent for those with low-fetuin-A, 18 percent for those with high CRP, 23 percent for those with low fetuin-A and high CRP, and 5 percent for those with neither low fetuin-A nor high CRP.

"In this large cohort of patients, we demonstrate that a severe inflammatory imbalance, characterized by a low fetuin-A concentration (anti-) and a high CRP concentration, is associated with a higher risk for death after ACS," Lim and colleagues write.

Several authors from the Lim study disclosed financial ties to the pharmaceutical industry.

More information: Abstract - Makrygiannis
Full Text
Abstract - Lim
Full Text

add to favorites email to friend print save as pdf

Related Stories

Fetuin-A levels linked to cardiovascular disease risk

Jan 08, 2013

(HealthDay)—In elderly individuals without type 2 diabetes, high levels of fetuin-A, a protein that inhibits arterial calcification and insulin action, is associated with a lower risk of cardiovascular ...

Recommended for you

Study: Removing clot helps limit stroke disability

5 hours ago

For the first time in several decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting ...

Growing shortage of stroke specialists seen

10 hours ago

Although stroke is the No. 4 cause of death and a leading cause of disability in the United States, there's an increasing shortage of neurologists who specialize in stroke care.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.